| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-410X.2010.09594.X |
| P698 | PubMed publication ID | 20875089 |
| P50 | author | Claudio Jeldres | Q37831565 |
| Felix Chun | Q39979798 | ||
| Steven Joniau | Q56435469 | ||
| Hendrik Isbarn | Q91728675 | ||
| Pierre I Karakiewicz | Q97332033 | ||
| Markus Graefen | Q97332035 | ||
| Hartwig Huland | Q97332101 | ||
| Alwyn M Reuther | Q114316431 | ||
| Hein Van Poppel | Q114316456 | ||
| Ofer Yossepowitch | Q114316554 | ||
| P2093 | author name string | Peter T Scardino | |
| Jochen Walz | |||
| Eric A Klein | |||
| Hsu Chao-Yu | |||
| P433 | issue | 5 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 765-770 | |
| P577 | publication date | 2010-09-28 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy | |
| P478 | volume | 107 |
| Q93081525 | A Radiogenomic Approach for Decoding Molecular Mechanisms Underlying Tumor Progression in Prostate Cancer |
| Q41630001 | Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation |
| Q43177826 | Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors |
| Q39563575 | Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-sc |
| Q36690539 | Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer |
| Q87517848 | Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics |
| Q26866036 | Current clinical challenges in prostate cancer |
| Q34346841 | Current status of radical prostatectomy for high-risk prostate cancer. |
| Q64988730 | Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor. |
| Q39847815 | Early oncological and functional outcomes following radical treatment of high-risk prostate cancer in men older than 70 years: A prospective longitudinal study |
| Q37339657 | Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer |
| Q37485340 | Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy |
| Q38648500 | Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy |
| Q47369518 | Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes |
| Q88007829 | Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial |
| Q88197455 | Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer? |
| Q37509084 | Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades |
| Q47132562 | Increased expression of tumor protein D54 is associated with clinical progression and poor prognosis in patients with prostate cancer |
| Q39400229 | Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study |
| Q41334393 | Is radical prostatectomy a useful therapeutic option for high-risk prostate cancer in older men? |
| Q35847743 | Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer |
| Q43427594 | Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer |
| Q35503645 | Management of high-risk localized prostate cancer |
| Q37528968 | Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospect |
| Q40897976 | Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. |
| Q42122312 | Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature |
| Q93036248 | Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers |
| Q58593662 | Pathological outcomes and biochemical recurrence-free survival after radical prostatectomy for high-risk prostate cancer in the Indian population |
| Q42789255 | Posterior reconstruction and outcomes of laparoscopic radical prostatectomy in a high-risk setting |
| Q53660770 | Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. |
| Q50769648 | Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer. |
| Q42103015 | Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL. |
| Q49567841 | Radical prostatectomy in locally advanced prostate cancer |
| Q38684701 | Radical prostatectomy: an option for high-risk prostate cancer |
| Q38278140 | Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer |
| Q49211987 | Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry. |
| Q37581405 | Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score |
| Q34453371 | Role of robot-assisted radical prostatectomy in the management of high-risk prostate cancer |
| Q46333989 | Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer |
| Q35220192 | Surgery for high-risk localized prostate cancer |
| Q101564382 | Surgical management of high-risk, localized prostate cancer |
| Q38374417 | The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer |
| Q26849794 | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer |
| Q38952181 | The very-high-risk prostate cancer: a contemporary update |
| Q98232230 | Three-tiered sub-classification system of high-risk prostate cancer in men managed with radical prostatectomy: Implications for treatment decision-making |
| Q58556664 | Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy |
| Q52855360 | [Multimodal therapy of locally advanced prostate cancer]. |
| Q85273029 | [Sexuality and prostate cancer] |
Search more.